Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 766-768, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balasubramanian, P.
Right arrow Articles by Chandy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balasubramanian, P.
Right arrow Articles by Chandy, M.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 2001;47:766-768.)
© 2001 American Association for Clinical Chemistry, Inc.

Technical Briefs

Stability of Busulfan in Frozen Plasma and Whole Blood Samples

Poonkuzhali Balasubramaniana, Alok Srivastava1 and Mammen Chandy1

1 Department of Hematology, Christian Medical College Hospital, Vellore, India
a author for correspondence: fax 91-416-232035, e-mail bala@hemato.cmc.ernet.in

Busulfan is widely used as a component of myeloablative conditioning therapy for bone marrow transplantation (1)(2)(3)(4)(5). Busulfan is most often used at a fixed total dose of 16 mg/kg. Wide interindividual variation in the bioavailability of busulfan has been recognized. Pharmacokinetic analyses to achieve target plasma concentrations and dose adjustments are increasingly being used to improve the outcome of bone marrow transplantation (6)(7)(8). Studies on busulfan kinetics have demonstrated that busulfan concentrations in stored plasma samples are stable for up to 3 months at -20 °C and that blood samples for busulfan analysis should be centrifuged within 3 h of collection and plasma frozen if not analyzed immediately (9)(10)(11). The stability of busulfan in blood and plasma samples stored for longer time periods and at lower temperatures has not been reported. Because pharmacokinetic analysis of busulfan requires collection of multiple samples at frequent intervals, such data will be useful in planning transport and analysis of blood and plasma samples.

This study was undertaken to determine the stability of busulfan in whole blood samples stored up to 24 h at 4 °C and in plasma samples stored up to 2 years at -80 °C.

Busulfan analysis was performed on plasma samples by HPLC as described previously (12). Briefly, busulfan in plasma was extracted with toluene and . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.